Clinical Practice Surveillance of the Use of Herceptin® Subcutaneous in Patients With HER2-Positive Early Breast Cancer (HerSCin)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms HerSCin
- Sponsors Roche
- 24 Apr 2017 Planned End Date changed from 1 Jul 2016 to 1 Jul 2018.
- 24 Apr 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2018.
- 07 Jun 2016 Interim results (n = 130) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.